Connor, Clark & Lunn Investment Management (CC&L)’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
|
|||||
|
2022
Q2 | $16K | Sell |
|
|||||
|
2022
Q1 | $163K | Buy |
|
|||||
|
2021
Q4 | $387K | Buy |
|
|||||
|
2021
Q3 | $462K | Buy |
|
|||||
|
2021
Q2 | $414K | Buy |
|
|||||
|
2019
Q3 | – | Sell |
|
|||||
|
2019
Q2 | $267K | Sell |
|
|||||
|
2019
Q1 | $1.09M | Sell |
|
|||||
|
2018
Q4 | $683K | Buy |
|
|||||
|
2018
Q3 | $1.41M | Buy |
|
|||||
|
2018
Q2 | $1.05M | Buy |
|
|||||
|
2018
Q1 | $744K | Buy |
|
|||||
|
2017
Q4 | $142K | Buy |
|